Who are Neupro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): levodopa/dopa decarboxylase inhibitor, Rotigotine transdermal patch, Levodopa Benserazide Teva Italia, ROP+L-Dopa, Dopamine Agonists, Neupro®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rotigotine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Neupro — Competitive Intelligence Brief

Neupro (ROTIGOTINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonergot Dopamine Agonist [EPC]. Area: Neuroscience.

marketed Nonergot Dopamine Agonist [EPC] dopamine receptors Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Neupro (ROTIGOTINE) — UCB. Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neupro TARGET	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)
Rotigotine transdermal patch	Rotigotine transdermal patch	UCB BIOSCIENCES GmbH	marketed	Non-ergot dopamine agonist	Dopamine receptors (D1, D2, D3, D4, D5)
Levodopa Benserazide Teva Italia	Levodopa Benserazide Teva Italia	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine)
ROP+L-Dopa	ROP+L-Dopa	GlaxoSmithKline	marketed	Dopamine agonist + Levodopa combination	Dopamine receptors (D2/D3); Dopamine pathway
Dopamine Agonists	Dopamine Agonists	Leiden University Medical Center	marketed	Dopamine agonist	Dopamine receptors (D1-D5)
Neupro®	Neupro®	UCB Pharma	marketed	Dopamine agonist	Dopamine receptors (D1, D2, D3, D4, D5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonergot Dopamine Agonist [EPC] class)

UCB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neupro — Competitive Intelligence Brief. https://druglandscape.com/ci/rotigotine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab